Only one ENZC shareholder could bring the huge experienced biotech firm’s value down to historical lows. Fortunately, the case is recently closed in favor of the company. Its CEO says the court’s decision was made to support all the shareholders’ interests and the company has sufficient time to focus on science and technology.
This year Enzolytics has obviously tried to commercialize its IPF Immune to the US with an intention to support the overall immunity of post-covid-19 patients. No financial gains have been so far made by the company since it is still at the “cash-burning” level. For the last quarter, the stockholders are most likely expecting any revenue achievements.